Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth

View original at seekingalpha.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth Earnings Call Insights: RadNet, Inc. (RDNT) Q3 2025 MANAGEMENT VIEW * CEO Howard Berger opened by stating, "I am very pleased with the performance in the third quarter…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RadNet needs more sales personnel post-iCAD acquisition, and margin expansion will increasingly be driven by digital health tools.

    80% confidence
  • Aggregate MRI volume increased 14.8%, CT volume increased 9.4%, and PET/CT volume increased 21.1% from Q3 2024.

    80% confidence
  • Total company revenue increased 13.4% and adjusted EBITDA increased 15.2% relative to Q3 2024, resulting in a 26 basis point improvement in adjusted EBITDA margins.

    80% confidence
  • RadNet increased imaging center revenue guidance by $50 million at the low end and $30 million at the high end, and increased adjusted EBITDA guidance by $5 million at both ends.

    80% confidence
  • RadNet operates 407 centers as of September 30, 2025, with one new center opened during Q3 and 4.9% total same-center procedure volume growth.

    80% confidence
  • Advanced imaging volumes increased 13.0% on an aggregate basis and 9.9% on a same-center basis, driven by equipment upgrades, AI-driven scheduling, capacity expansion, and shift from hospital to ambulatory imaging.

    80% confidence
  • 2026 Medicare reimbursement changes will benefit RadNet with approximately $4-5 million revenue uplift on roughly $2 billion of revenue.

    80% confidence
  • EBCD payer adoption discussions are progressing positively with increasing traction, though large payers move slowly.

    80% confidence
  • Exposure to Medicaid and health insurance exchanges is minimal, reducing risk from policy changes.

    80% confidence
  • EBCD AI revenue rose 28.7% year-over-year.

    80% confidence
  • AI revenue within Digital Health, inclusive of iCAD revenue from ProFound AI and Deep Health solutions, increased 112% from Q3 2024.

    80% confidence
  • Digital Health revenue increased 51.6% from Q3 2024, partially due to iCAD's revenue contribution since July 17 acquisition.

    80% confidence
  • DSOs (Days Sales Outstanding) reduced to 31.9 days, the lowest historical level for RadNet.

    80% confidence
  • See-Mode's thyroid ultrasound technology achieved a 30% reduction in scan time across 240+ centers.

    80% confidence
  • Labor markets for radiology technologists remain challenging but have stabilized, and RadNet is seeing increasing inbound calls from health systems for partnership opportunities.

    80% confidence
  • Virtual radiology is an inevitability, and DeepHealth serves as a platform to bundle and integrate multiple AI modules for both internal and external customers.

    80% confidence
  • iCAD contributed approximately $3.9 million in revenue during Q3 2025.

    80% confidence
  • Adjusted EBITDA margins increased by 26 basis points from 16% to 16.2% year-over-year.

    80% confidence
  • TechLive rollout should be substantially complete by the end of 2025, and has reduced exam closure hours by about 42% relative to last year.

    80% confidence
  • PET/CT growth is driven by PSMA and amyloid brain studies, which now make up 20% of PET/CT volume.

    80% confidence
  • Cash balance as of September 30, 2025 was $804.7 million with net debt to adjusted EBITDA ratio of approximately 1.0.

    80% confidence
  • Q3 2025 revenue and adjusted EBITDA were both quarterly records and exceeded internal budgets set at the beginning of 2025.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth — Source | Via News | ViaNews Market